{"id":"NCT03046446","sponsor":"Pacira Pharmaceuticals, Inc","briefTitle":"Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee","officialTitle":"An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients With Osteoarthritis of the Knee","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-20","primaryCompletion":"2018-07-19","completion":"2018-07-19","firstPosted":"2017-02-08","resultsPosted":"2019-10-29","lastUpdate":"2024-01-24"},"enrollment":208,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis of the Knee"],"interventions":[{"type":"DRUG","name":"FX006 32 mg","otherNames":[]}],"arms":[{"label":"FX006 32 mg","type":"EXPERIMENTAL"}],"summary":"This is an Open-label Study to Assess the Safety of Repeat Dose of FX006 Administered to Patients with Osteoarthritis (OA) of the Knee","primaryOutcome":{"measure":"Total Number of Treatment Emergent Adverse Events (TEAEs) in Patients With Symptomatic Osteoarthritis (OA) of the Knee Who Received Two Doses of 32 mg FX006","timeFrame":"Up to 52 Weeks","effectByArm":[{"arm":"FX006 32 mg","deltaMin":336,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":12},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":["30741382"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":208},"commonTop":["Arthralgia","Upper respiratory tract infection","Muscle spasms","Back pain","Joint swelling"]}}